DUBLIN, Jan. 5, 2015 /PRNewswire/ -- Jazz Pharmaceuticals
plc (Nasdaq: JAZZ) today announced that the company will be
webcasting its corporate presentation at the 33rd Annual
J.P. Morgan Healthcare Conference in San
Francisco, CA.
Bruce C. Cozadd, chairman and
chief executive officer, will provide an overview of the company
and provide a business and financial update at the conference on
Monday, January 12, 2015 at
10:00 a.m. PST / 6:00 p.m. GMT.
A live audio webcast of the presentation may be accessed from
the Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com. Please connect to the website prior to
the start of the presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
webcast.
An archive of the webcast will be available for at least one
week following the presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international
biopharmaceutical company focused on improving patients' lives by
identifying, developing and commercializing meaningful products
that address unmet medical needs. The company has a diverse
portfolio of products and/or product candidates with a focus in the
areas of sleep and hematology/oncology. In these areas, Jazz
Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and
Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S.,
and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S.
For more information, please visit www.jazzpharmaceuticals.com.